Levels of annexin IV and V in the plasma of pregnant and postpartum women

Summary

Annexin (Anx) V is pivotal in the maintenance of pregnancy by preventing the activation of blood coagulation. The homology of the amino acid sequence between Anx IV and Anx V is highest in Anx family proteins. However, little is known about the roles of Anx IV in pregnancy.The aim of this study is to clarify the roles of circulating Anx IV and Anx V in normal pregnancy. Subjects were non-pregnant women (n = 50), 120 pregnant women, and maternal subjects just after delivery (n = 53) or postpartum (n = 67). Anx IV in the plasma of non-pregnant women was at a concentration 20 times that of Anx V. The plasma levels of Anx IV suddenly increase after delivery, but Anx V levels remain low during this period. Anx IV and Anx V exert similar levels of anticoagulant activity. Anx IV protein was expressed on the basal surface of syncytiotrophoblasts; Anx V protein, on the apical surface of syncytiotrophoblasts. These results suggest that Anx IV enters the maternal bloodstream just after delivery and might play a role in preventing disseminated intravascular coagulopathy, and that Anx V helps to prevent clotting in the placenta during pregnancy.

Keywords

Disseminated intravascular coagulopathy (DIC) - pregnancy - annexin - anticoagulant

• References

• 1 Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002; 82: 331-71.
• 2 Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-32.
• 3 Letsky EA. Disseminated intravascular coagulation. Best Pract Res Clin Obstet Gynaecol 2001; 04: 623-44.
• 4 Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90: 29-37.
• 5 Gharavi AE. et al. Mechanisms of pregnancy loss in antiphospholipid syndrome. Clin Obstet Gynecol 2001; 44: 11-9.
• 6 Satoh A. et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999; 26: 1715-20.
• 7 Kraus M. et al. Detection of human antiannexin autoantibodies by enzyme immunoassays. J Immunoassay 1992; 13: 411-39.
• 8 Bastian BC. et al. Autoantibodies to annexins: a diagnostic marker for cutaneous disorders?. J Dermatol Sci 1994; 08: 194-202.
• 9 Dubois T. et al. High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1230-4.
• 10 Donohoe S. et al. Ontogeny of beta 2 glycoprotein I and annexin V in villous placenta of normal and antiphospholipid syndrome pregnancies. Thromb Haemost 2000; 84: 32-8.
• 11 Kojima K. et al. Affinity purification and affinity characterization of carbohydrate-binding proteins in bovine kidney. J Chromatogr 1992; 597: 323-30.
• 12 Kojima K. et al. Characterization of carbohydrate-binding protein p33/41: relation with annexin IV, molecular basis of the doublet forms (p33 and p41), and modulation of the carbohydrate binding activity by phospholipids. J Biol Chem 1996; 271: 7679-85.
• 13 Kojima K. et al. Highly polarized expression of carbohydrate-binding protein p33/41 (annexin IV) on the apical plasma membrane of epithelial cells in renal proximal tubules. FEBS Lett 1994; 342: 313-8.
• 14 Ishitsuka R. et al. Glycosaminoglycan binding properties of annexin IV, V, and VI. J Biol Chem 1998; 273: 9935-41.
• 15 Tsujii-Hayashi Y. et al. A potential endogenous ligand of annexin IV in the exocrine pancreas. Carbohydrate structure of GP-2, a glycosylphosphatidy-linositol-anchored glycoprotein of zymogen granule membranes. J Biol Chem 2002; 277: 47493-9.
• 16 Satoh A. et al. Modulation of cell surface lectin receptors on K562 human erythroleukemia cells induced by transfection with annexin IV cDNA. FEBS Lett 1997; 405: 107-10.
• 17 Satoh A. et al. Expression of carbohydratebinding protein p33/41 in human tumor cell lines. J Biochem (Tokyo) 1996; 119: 346-53.
• 18 Satoh A. et al. Characterization of human p33/41 (annexin IV), a Ca2+ dependent carbohydrate-binding protein with monoclonal antiannexin IV antibodies, AS11 and AS17. Biol Pharm Bull 1997; 20: 224-9.
• 19 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
• 20 Lockwood CJ. et al. Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am J Obstet Gynecol 1991; 165: 1335-41.
• 21 Dobado-Berrios PM. et al. The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 2001; 44: 2467-76.
• 22 Bellart J. et al. Tissue factor levels and high ratio of fibrinopeptide A:D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia. Br J Obstet Gynaecol 1999; 106: 594-7.
• 23 Bellart J. et al. Endothelial cell markers and fibrinopeptide A to D-dimer ratio as a measure of coagulation and fibrinolysis balance in normal pregnancy. Gynecol Obstet Invest 1998; 46: 17-21.
• 24 Levi M. et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
• 25 von Kanel R, Dimsdale JE. Fibrin D-dimer: a marker of psychosocial distress and its implications for research in stress-related coronary artery disease. Clin Cardiol 2003; 26: 164-8.
• 26 Andrew M, Mitchell L, Berry L. et al. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 1992; 89: 321-6.
• 27 Lakasing L. et al. Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome. Am J Obstet Gynecol 1999; 181: 180-9.
• 28 Rand JH. et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood 1998; 92: 1652-60.
• 29 Rand JH. et al. Pregnancy loss in the antiphospholipid-antibody syndrome – a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154-60.
• 30 Römisch J. et al. Anticoagulant properties of placenta protein 4 (annexin V). Thromb Res 1990; 60: 355-66.
• 31 Van Ryn-McKenna J. et al. The effects of heparin and annexin-V on fibrin accretion after injury in the jugular veins of rabbits. Thromb Haemost 1993; 69: 227-30.
• 32 Flaherty MJ. et al. Placental anticoagulant protein-I: measurement in extracellular fluids and cells of the hemostatic system. J Lab Clin Med 1990; 115: 174-81.
• 33 Goulding NJ. et al. Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone. Lancet 1990; 335: 1416-8.
• 34 Tait JF. et al. Placental anticoagulant proteins: isolation and comparative characterization four members of the lipocortin family. Biochemistry 1988; 27: 6268-76.
• 35 Rand JH, Wu XX. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999; 82: 649-55.
• 36 Knoll BJ. Gene expression in the human placental trophoblast: a model for developmental gene regulation. Placenta 1992; 13: 311-27.
• 37 Wang X. et al. Secretion of annexin V from cultured cells requires a signal peptide. Placenta 2001; 22: 837-45.